Esperion's (ESPR) Drugs Get EU Nod for Lowering Heart Risk [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance
its drugs Nilemdo (bempedoic acid) and Nustendi for the treatment of hypercholesterolemia and to reduce the risk of adverse cardiovascular (CV) events. Hypercholesterolemia indicates elevated levels of cholesterol in the blood. Following the label expansion in Europe, Nilemdo and Nustendi became the first and only treatments for lowering low-density lipoprotein cholesterol (LDL-C), also known as bad cholesterol, approved for primary and secondary prevention of CV events. Additionally, the updated labels support the use of Nilemdo and Nustendi either alone or in combination with statins. Please note that Nustendi is a fixed-dose combination of bempedoic acid and ezetimibe. The latest EC approval was based on positive data from the phase III CLEAR Outcomes study. Data from the same showed that treatment with Nilemdo and Nustendi led to a 13% reduction in the relative risk of major adverse CV events defined as a four-component composite of death from CV causes, non-fatal myocar
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Why Is Esperion Therapeutics (ESPR) Up 14.2% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Esperion to Participate in Upcoming June Investor ConferencesGlobeNewswire
- First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk [Yahoo! FinYahoo! Fin
- First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular RiskGlobeNewswire
- Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.MarketBeat
ESPR
Earnings
- 5/7/24 - Beat
ESPR
Sec Filings
- 6/12/24 - Form SC
- 5/28/24 - Form 8-K
- 5/24/24 - Form 4
- ESPR's page on the SEC website